Core Insights - TC BioPharm is a clinical-stage biotechnology company focused on developing allogeneic gamma-delta T cell therapies for cancer treatment, with a specific emphasis on acute myeloid leukemia [2][3] Company Overview - TC BioPharm (Holdings) PLC is engaged in discovering, developing, and commercializing gamma-delta T cell therapies, which are immune cells that can differentiate between healthy and diseased tissue [2] - The company is recognized as a leader in the development of gamma-delta T cell therapies and is the first to conduct phase II/pivotal clinical studies in oncology [3] Clinical Trials - TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for treating acute myeloid leukemia using its proprietary allogeneic CryoTC technology [3]
TCBP to Present at Sequire Investor Summit 2025